New hope for rare blood disorder: crovalimab trial underway
NCT ID NCT03157635
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests a new medicine, crovalimab, for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. It involves healthy volunteers and people with PNH to check safety and how well the drug works. The goal is to control the disease, not cure it, and participants will need ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL HEMOGLOBINURIA, NOCTURNAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis
Paris, 75475, France
-
Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology
Kaposvár, 7400, Hungary
-
NTT Medical Center Tokyo
Tokyo, 141-8625, Japan
-
Osaka University Hospital
Osaka, 565-0871, Japan
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Pra International Group B.V
Groningen, 9713 GZ, Netherlands
-
Semmelweis Egyetem, 1. Szamu Belgyogyaszati Klinika, Diabetologia
Budapest, 1083, Hungary
-
Seoul National University Hosp
Seoul, 110-744, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Tohoku University Hospital
Miyagi, 980-8574, Japan
-
Tokyo Medical University Hospital
Tokyo, 160-0023, Japan
-
Uniklinik RWTH Aachen
Aachen, 52074, Germany
-
University of Tsukuba Hospital
Tsukuba, 305-8576, Japan
-
Universitätsklinikum Essen
Essen, 45122, Germany
-
Universitätsklinikum Ulm
Ulm, 89081, Germany